The identification of key metabolic pathways, including the novel finding of citric acid elevation and its interaction with the MIF gene, offers promising avenues for the development of targeted therapeutic strategies and the improvement of clinical outcomes for lung cancer patients. This evidence concerns the gene MIF and lung carcinoma.